Bobby Sandage

Bobby W Sandage, Jr., PhD, is an accomplished professional with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Interim Head of Development and Board Member at AI Proteins since July 2022, Sandage also holds board positions at Microbial Machines, NextRNA Therapeutics, Geneoscopy, and BioVentures, LLC. As Managing Director of the Paula and Rodger Riney Foundation, Sandage is dedicated to finding a cure for multiple myeloma. In addition, as General Partner at Cultivation Capital Life Sciences Fund II since September 2016, Sandage focuses on advancing early-stage life sciences companies. Sandage's leadership as President and CEO of Euclises Pharmaceuticals, Inc. emphasizes the development of novel oral treatments for COX-2/PGE-2 driven cancers. Educational credentials include a Ph.D. in Clinical Pharmacy from Purdue University and a BS in Pharmacy from the University of Arkansas for Medical Sciences.